MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


AstraZeneca, Daiichi Sankyo gastric cancer drug wins approval in US

StockMarketWire.com

Pharmaceutical giants AstraZeneca and Daiichi Sankyo said their gastric cancer drug had been approved in the US.

The approval of enhertu by the Food and Drug Administration was based on positive results froma Destiny-Gastric01 phase-two trial conducted in Japan and South Korea.

Following US approval, AstraZeneca was due to pay $115 million to Daiichi Sankyo as part of a combined second-line and third-line milestone payment.





Story provided by StockMarketWire.com